Reddit Posts
CRMD CorMedix down -40 percent after CEO becomes chair.
CRMD Put it on your watchlist, big gap down on flat revenue forecast for 2026, has Phase 3 readout for additional indication due late 2026, TRAILING PE OF 3, I see value in this one buy and hold play!
CRMD Potential Breakout today! Target 180% move!
CRMD, massive EPS beat and last reported 22% of the float was shorted.
$45,000 YOLO on $CRMD. profitable company with no Debt should be priced at $270. you can get it now for $11.30
CRMD bullish news on prelimanary results
Is CRMD (CorMedix) a potential squeeze?
CRMD potential squeeze or is the float too big?
$CRMD-Cormedix Biotech Potential Short Squeeze Incoming
TLPH - did my DD and research, looking into buy in and need your opinions!
CorMedix: From Cash Blowing to Bear Back Blowing
CorMedix: From Cash Blowing to Bear Back Blowing
CRMD down 60% , why and what. Analyst target at 500% upside.
Imagine being a bagholder in CRMD from the top
CRMD has a PDUFA date this month; analyst gives it 75% upside
CRMD has a PFUFA date this month; analyst gives it 75% upside
Mentions
A very optimistic outlook, yes maybe a 3-4x isnt possible but the chances of CRMD buying out TLPH is very possible due to the synergy that Nafamostat and defencath (CRMD product) has. The CEO of CRMD is also a BOD of TLPH. All the stars line up to a buyout agreement.
Man I feel you lol I took a long break and am gunna jump back in soon. And the year I took my money out I told a buddy he should put 10k in 2 that I “knew” had long term value and both have consistently gone up since I sold 😅 I want to grab CRMD rn but won’t have the extra money for a little bit so I almost guarantee it’s gunna go crazy after their full year financials on the 5th
I tend to look more at smaller / less crowded names rather than the obvious mega caps. A few I own (higher risk, obviously): LFMD – Telehealth / men’s health. I like the direct-to-consumer model and the margin expansion story if they keep scaling efficiently. Not saying it’s risk-free, but if they execute, it can re-rate. ABCL – AI-driven antibody discovery. This one is more of an asymmetric bet for me. If their platform consistently produces viable drug candidates and partnerships convert, upside could be significant. Still very biotech-risk heavy. GAMB – Gambling.com Group. Asset-light affiliate model in online betting. Solid cash generation and operating leverage if the U.S. market continues expanding state by state. CRMD – Small-cap biotech with a commercial product (DefenCath). This is more of a “commercial ramp” thesis. If adoption grows steadily, it could surprise people. If not, it’s dead money. All of these are volatile and definitely not “sleep well at night” positions — but that’s kind of the tradeoff for looking outside the usual Google/Amazon names. Just my approach.
Virtually everything is down right now, but some I'd investigate are: FBYD - Falcon Beyond Global Janux OWL CRMD
CRMD massively undervalued, trading at a discounted price - imma buy some share for long term. Any thoughts?
After CRMD I've gone back to being really cautious around smaller pharma names. Just totally out of my wheel house and dependent on a single product.
Get on the CRMD before it takes off!
$CRMD obviously. Can’t go tits up. 🤡
CRMD is speed running toward the bottom, there outlook after this mornings news isn't very good especially with their accusation reducing prices in the spring.
How does CRMD go from $127M quarterly to $320M annually?
CorMedix (CRMD) reported Q4 preliminary net revenue Thursday of $127 million. Analysts surveyed by FactSet expected $128.3 million. The company said it expects 2026 revenue of $300 million to $320 million. Analysts surveyed by FactSet expect $435.7 million. CorMedix also named Chief Executive Joseph Todisco chairman of the board of directors, succeeding Myron Kaplan, who will become lead independent director, which is a new position on the board. Not good for CRMD.
CRMD ... +25% within one Montag...tasty
Split it among CRMD, BFLY and PFE and write monthly calls on PFE.
Long Call on CRMD with 12.80 breakeven
I invested in DJT, NVDA, GOOG, CRMD, and POET
Here are my ten: APH NEM TSM GOOG/GOOGL NVDA MRNA CRMD BE VTRS ARLO Check back next year to see how I did.
I like both of those. CRMD management seem confident in the revenue forecasts and if it happens that's a moonshot, this is trading at 1/4 of sector average or less. A true moonshot. Thanks for sharing I'm adding both to my watchlist.
As I read the suggestions of great stocks for 2026 I'm surprised by one thing: most of the suggestions are the biggest winners from last year. NBIS, RKLB, SMR..... So the consensus seems to be last year's winners will win big again. However, not a lot of gold related names in there which is interesting, and possibly telling. I'll throw out a few: ODD. Very few people are talking about the amount of stimulus written into the OBBB. We're probably looking at the highest tax refunds in awhile and people are going to spend that cash. Consumer names are beaten down by the recession talk but we're seeing above average Christmas shopping levels. Trucking. Huge amounts of capacity have come off the road. Tender rejections are the highest in years. Any kind of demand is going to spike rates. Biotech I own TWST and CRMD. Falling rates are generally good for biotech. Hopefully next year will provide some clarity on healthcare too.
ABL Trading at 8x forward earnings and growing 80% y/y. This thing should double just to achieve a market multiple, not factoring in the insane growth. CRMD Trading at 4x earnings due to concerns about long term earnings. They expect to have some longer term contracts signed in the first half of 2026.
CRMD released some test results: "Based on CorMedix's analysis of the data available through September 30, 2025, compared to historical controls, use of DefenCath demonstrated an overall 72% reduction in CRBSI, and a 70% reduction in hospitalizations secondary to CRBSI. The Company believes this represents a meaningful reduction in risk in some of the most vulnerable patients as well as a significant source of cost savings to the healthcare community and payors. CMS spends more than $3 billion per year on costs associated with CRBSI in the ESRD patient population, as the average CRBSI-related hospitalization is estimated to cost approximately $63,000, and up to $110,000 per incident when accounting for other sequelae." Part of the thesis around CRMD is that their drugs actually save their customers money by lowering infection rates, and this seems to back up that it's working. This thing is ready to explode if they announce pricing.
Small caps as far as the eye cam see... I own a ton of ABL, but it's still super cheap. It could double and be cheap. JXN is still below book value and shredding their share count. NATL is still at single digits forward earnings. I've started buying a few shares of TWST. Trucking is still pretty cheap. CRMD could explode if they get pricing certainty.
CRMD is coming to a big binary moment; TDAPA runs out in August, either moon on deal with Fresebius or big drill
CRMD-real world evidence results should be released in the next week or two. Could trigger a squeeze if they come back better than expected.
CRMD (CorMedix) a tenbagger.
No worries- with how often it happens on the various penny stock communities I don't blame you, I try not to P&D anything. I am interested in squeeze plays if I like the setup/potential but this wasn't that. I swing trade BTC adjacent stocks and jump in on catalysts momentum trades. Normally if I'm in a biotech it's because I like the trend line for it. CABA, RVPH, and FEMY are my favorites rn pennywise and I have PSTV and DRTS but with exception of FEMY I keep those positions to 1-2%. Have some other higher biotechs like CRMD and ABT (I like ABT for its relatively steady growth and think the exact acquisition is a good move as exact also had acquired genomic health in 2019. oncotype dx and cologuard are regularly used at Cleveland clinic and I could see ABTs global presence speeding growth/usage of these once they get regulatory approvals through)
What is your outlook on CRMD?
hey you do you but CRMD has gone from 29m shares in 2020 to 79m shares in 2025. It's not a one time thing is my point.
CRMD up above all the moving averages now.... looking to break out, $12 being the next resistance. Solid.
Making money today on the CRMD pump, not bad. At least something is working
I've been looking through healthcare names leading into next year... here's a few I'm watching: UFPT- I own and have been adding to this one. Some short term issues are behind them and management teased new business wins upcoming during the last call. CRMD- Should have pricing clarity by June. The market is clearly not expecting much at 4-5x earnings. I think this could 2-3x on good news, but probably not much downside. I own June calls. TWST- maker of synthetic DNA for research. If AI boosts discovery, their business will explode. No position yet. What is everyone else watching in the sector?
I got burned by CRMD years ago. Never again. Good luck.
https://preview.redd.it/n1mgw61s4u5g1.png?width=3493&format=png&auto=webp&s=550f1dd59b455ea542e6e0e8379ee1953aa397dd CRMD is executing very well, the revenue/earnings estimate charts look like Mount Everest and uts incredibly cheap IMO. my conservative DCF with a 15% discount rate says it should be worth thrice as much as right now
ODD- several year hold (already held for a year). Extremely cheap for its growth. ABL- extremely cheap. Extremely. Hope to hold for a few years, but $20 might warrant a trim. SJT- holding until it relates due to resumption of its dividend, hopefully in 2026. Possibly beyond because it's just going to gush cash. CRMD- bought June calls. It's extremely cheap due to fears of its pricing getting cut. I feel like when this issue is resolved, the price will rerate.
My recent buys: ODD ABL CRMD SJT
I heard about them when they IPOd... I've always had it in the too hard pile. I was fortunate that we were able to have a kid without any help, and that whole world is dizzying to me when I hear about it from friends. TWST actually came to my attention researching CRMD. There's a guy who writes about biotech a lot and it was one he's really interested in. It's actually putting up good margins and decent growth. More speculative than my usual style, but I'm still really fascinated by it.
Of course it is. Small-cap Biotech is a complete gamble. If the stock market is a casino, Biotech is the nude russian roulette taking place in the fucking basement. It’s bang or bust. They will never be priced in relation to fwd expectations because of the significant amount of risk and uncertainty. OTLK, PSTV, CRMD, NBP, are all good examples. The market is loaded with these kind of bets. I think it’s fun, threw couple of thousands to either be pleasantly surprised, or expectedly disappointed.
CRMD looks really interesting here. They are down on uncertainty of their pricing for H2 2026. At 4x earnings the market seems to be pricing in a decline in earnings. Even stable earnings should fetch 8-10x. So if their defencath pricing continues, this thing should rocket. The nice thing is that even at current prices, defencath saves it's users money by preventing catheter infections. It's really tempting to start slowly adding shares as $9.5 has proven to be support numerous times.
CRMD being shorted by the holders of convertible debt. Shorted down to a pe of 4.78. Analysts targets around 18, trades under 10. FWIW
TDAPA ruling did come out Thursday night. While it was a little better than expected, it wasn’t what everyone was hoping for. The add on payment for H2 2026 was decided to be 2.371, but only included numbers for first year of Defencath sales(July 24-July 25). The company had appealed CMS to include the last year of Defencath sales(including q3 and q4 of this year) because the use is so much higher therefore the add-on would be too. Of course they denied and now the market is waiting on guidance for next year from the company. Real world evidence study will be released before end of year(my theory is the Monday before Christmas) and they really need to be blow out numbers. As far as we know they are based on information available. Fresenius actually spent time during their last earnings talking about Defencath and CRMD without specifically naming them, just that they have started new treatments geared towards patient safety and infection prevention.
I was buying NATL recently, I think it's super cheap and they're turning on the buyback machine, which is really helpful in this environment. SJT is interesting with nat gas being hot. When they restart the dividend I expect good things. I've also been buying ODD. Chart is terrible, but I can't resist adding to my position down here. It's too cheap. Otherwise I'm being very discerning right now. Everything I look at has a Terrible chart and I'm not particularly bullish. CCOI is cheap, but plummeting. SHLS is interesting, but not super cheap. ABL is dirt cheap, but I own a ton already. CRMD is one I'n really interested in, but I'm still evaluating it. It looks too obvious and I'm sure I'm missing something.
Thanks really useful info, I'm not gonna lie I'm a bit uneasy about CRMD at the moment but I'm just hoping for a near-term rally so I can hopefully cash out a small gain. I think the long term prospects are a coin flip at this point
CRMD burns cash 2022 Operating Cash Flow minus $24,000,000 2023 Operating Cash Flow minus $38,000,000 2024 Operating Cash Flow minus $50,600,000 79,000,000 shares outstanding What do you do to get more cash? Secondary Offerings and Convertible Notes Convertible notes were valued at $13.50 a share Cormedix keeps adding more shares and burning through cash. Cormedix went public in 2010. Reached a high of $50 in 2015. Crashed to $4 in 2023. The IPO was 2,000,000 shares, since then the company keeps diluting shares. Strong earnings, but is it because of Defencath or the acquisition of Melinta and its rights to drug Rezzayo? Will Merck stops the rights to Rezzayo since it bought Cidara, who created the drug Rezzayo. It is a biopharma, high risk, high reward.
I'm presuming they're betting on post-TDAPA reduction or failure of Rezzayo: Rezzayo has not yet generated any revenue because it is a product in the clinical trial phase. CorMedix (CRMD), the company developing Rezzayo, reported its most successful quarter to date with **$104.3 million in net revenue** for Q3 2025, which was driven by its other product, DefenCath. * **Rezzayo is a pipeline product**: The company is awaiting top-line data from its Phase III ReSPECT study for Rezzayo, which is expected in the second quarter of 2026. * **Future revenue potential**: The company estimates the total addressable market for Rezzayo in antifungal prophylaxis is over $2 billion and debt is actually higher than my shallower dive showed so they still need to still get that in line.
CRMD continuously comes up on my screeners for fundamentals I prioritise. However, I generally stay away from biotech. I wish you good luck though.
I'm all in on CRMD. It's undervalued for sure at the moment and I'm hoping it to hit $13 - $14 within the next 6 months. Worth mentioning the risks though - * Their main product is currently being subsidised by Medicare and they will need to negotiate in 2026 about the future pricing which could obviously hit revenues hard * The product also has a shallow moat and any of the big bio techs could move into the space and develop their own version * They are in litigation at the moment over securities fraud. Relates to an issue they had with their manufacture of the product a few years ago and potentially hiding problems from shareholders * Their alternate products are going through evaluation and as with all Biotech, they could fail at the final hurdle and be left with nothing * Finally, there is a potential stock dilution on the horizon So TDLR; it's a great opportunity but definitely not without risk. If everything goes well then it could easily be a 10 bagger but if any of the above doesn't go well then it could easily become a penny stock.
Time will tell unfortunately, I'm just making sure im not too heavily into BTC or AI rn and allocating to companies with good growth prospects outside of the fears and keeping my investment thesis to mostly hold longer term. I'm currently loading up on CRMD as I think that one will steadily rise long term, low P/E, profitable, and a good plan for diversifying revenue/increasing growth.
the shear amount of shorting across the board just means you need to put your money in things that aren't trading at high forward P/E's. That's why im shunting more towards CRMD right now. Massively shorted, profitable company with a good earnings call. consensus of buy and avg price tgt of 18.33. P/E is 5.4. I can have confidence in holding this one through the turmoil.
Forgot to post the earnings, but CRMD threw down another great report. $1.25 quarterly adj. EPS on an $11 stock is nuts. Another way to look at it...$108 million in quarterly net income on an $800 million company. Insanely cheap.
Whoever shouted about CRMD, thank you, looks like a winner after those blowout earnings...Glad I bought in...
CRMD its being squees... Short float @ >20%
[https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix\_biotech\_potential\_short\_squeeze/?utm\_source=share&utm\_medium=web3x&utm\_name=web3xcss&utm\_term=1&utm\_content=share\_button](https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix_biotech_potential_short_squeeze/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button) I went into it a little bit a couple months ago and still think it could squeeze, but not from this. I've been in the stock for over 3 years and these numbers are insane and pt should be a lot more, but there was a shelf offering in June right after LDO1 was signed and an acquisition of Melinta. The dark cloud hanging over it right now is CMS TDAPA reimbursement news. CRMD has requested an extension and updated pricing for post TDAPA which will begin next summer. If they get good news, it could seriously take off. Also, real world evidence study results will be released by the end of year. If that comes back as we all hope, showing that it prevents infections at the rate it does, it could pop as well. While I do think we'll see nice movement today, I don't think the true value and squeeze will come until the CMS decision is released.
VIVK a good play this week. Huge volume on monday with no real price movement = institutional accumulation. Was expecting something yesterday but it was a pretty flat day across the board. Holding strong for now. Trimming FEMY, CRMD, and HUMA today if these good ERs fetch me some profit and I’ll load up on more VIVK if price is still stable. Got a good feeling about this one.
glad i bought yesterday CRMD, hope it will continue the growth
CRMD predictions for Wednesday?
CRMD easiest bet of my life. FWD P/E of 4 for a biotech! Buy and win with me!
For the most part I swing trade MARA and SOFI (avoiding SOFI rn tho due to recent EPS and not establishing new lower/higher resistance levels yet) I take stabs at promising penny set ups and roll any profits into more SOFI shares or AMZN/GOOG/ CRMD
Informed Insider buys at CorMedix leading up to earnings report I implore you to look into CRMD. I will not shill. #CorMedix
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
$CRMD make me so HOOOORRRRRRRNNNNNNYYYYYY
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
Lets pump CRMD back to ATH of $49
CorMedix is rated top biopharma-turned-tech company. #All in on CRMD.
Bullish here too. Notably, the technicals are pointing to a burst of buying interest. **Moving Average Momentum:** Very recently, CRMD's 73 Day moving average shot above its 78 moving average. In the past, when this happened, CRMD tended to climb about 2.62% the next day on average, with a high statistical confidence (p-value of 0.00388). This pattern has appeared 52 times in the past. This suggests a burst of buying interest. **Moving Average Resistance:** CRMD's 105 Day moving average is now touching its 106 moving average. This contact is flagged as a potential mean-reversion setup, often signaling short-term strength. Historically, CRMD climbed about 1.67% the next day on average, with a high statistical confidence (p-value of 0.00971), across 98 past cases. These are all from [**SiriusAI**](http://www.siriussignals.com) but worth noting!
Good morning! I've been in CRMD for over 3 years and posted about it 3 weeks ago. That post is [here](https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix_biotech_potential_short_squeeze/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button) . Just wanted to clarify some things about it. Yes, this is amazing news and shows sales are better than expected even a month ago when they raised guidance the first of September. Defencath utilization is better than expected for the LDO1, which is huge news too. However, the most important news for the stock in the short term is the CMS TDAPA reimbursement decision. If it comes back negative, it would prevent any squeeze whatsoever. If it comes back the way we hope, then we would probably see it. Also, potential short term catalysts (if TDAPA decision is neutral or not as good as expected) would be LDO2 sign on, Real world study results and FDA approval on Rezzayo. Keep in mind, that while the deadline for the TDAPA decision was November 1, that could be delayed due to the government shutdown. I'm not posting these things to dissuade anyone from getting in the stock, just wanting to clarify the picture. CRMD has exceeded sales since last July when they began, but the stock always gets beaten back down. Even with the news this morning, we're still sitting lower than at the beginning of October(and much less than the beginning of September even after raising guidance).
Ah, CRMD- haven't seen that ticker for like 5+ years when I was gambling on trash penny stocks. It's still trash. Run from all these unless you hate making money.
Today's Buys: NEXM, CRMD, ALMS, FRSH
Short CRMD. They're diluting by 50%
#CorMedix (CRMD) ● Debt:equity = 0.00 (no debt) ● revenue up 5,000% ● current margins = 50% ● projected margins of 85-95% ● forward PE of 7.0
Hey man nice informative post. I was also looking at opening a position on TLPH purely on the speculation of FDA approval and CRMD acquisition, however I wasnt sure whether current price is good or whether I should wait for a pull back down to about $0.70
The safest investment on the market right now is CorMedix (CRMD)
JMP Securities analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $22 price target.
TLPH - Talphera, Inc \>Link [https://talphera.com/](https://talphera.com/) scroll down to view pipeline \>I'm looking forward on this and need everyone opinions on this! **January 2025** Lead candidate Niyad™ (nafamostat mesylate), FDA granted Breakthrough Device Designation in January 2025. Nafamosta (raw drug, generical chemical) widely used in Asia for decades. The distinction of Niyad would be on US first FDA FDA-approved regional anticoagulant for CRRT in ICU patients (if approved). At present in the US doctors used unapproved workarounds. FDA designation and immediate commencement of Phase 3 is probably FDA recognized the real world usage and decades of use in Asia. Hence, the risk of failure is low. **Catalyst** End of 2025, Phase 3 result positive > PMA target filling in first half of 2026 > FDA decision 2nd half of 2026. \*in between 60 days post phase 3 result, there is possibilities on CRMD looking to buy TLPH\* **Where the RISK?** Reverse split, they need to meet min bid 1.0 by December 1 2025. The price about to reach 1.0, and it must maintain it for 10 consecutive business days! [https://ir.talphera.com/static-files/1774ca90-a5c3-41b4-af85-4661c4dcff9c](https://ir.talphera.com/static-files/1774ca90-a5c3-41b4-af85-4661c4dcff9c) Upcoming Annual Meeting to vote for RS - preliminary, and date set on October 23 2025. [https://ir.talphera.com/static-files/1c6ab3cd-ee27-42b2-8b7e-a4fe04e19055](https://ir.talphera.com/static-files/1c6ab3cd-ee27-42b2-8b7e-a4fe04e19055) **August 2025** TLPH is now enrolling patient and on track for study completion by end of 2025. Main catalyst! The size of patients was FDA-approved reduction in required sample size - from 166 to 70. [https://ir.talphera.com/news-releases/news-release-details/talphera-announces-achievement-17-patient-enrollment-milestone](https://ir.talphera.com/news-releases/news-release-details/talphera-announces-achievement-17-patient-enrollment-milestone) Recent news, CRMD together with other new and existing investors made an equity investment in TLPH via private placement. This provide TLPH sufficient capital through approval of Niyad in the second half of 2026. The private placement also provided CRMD; "60 days exclusivity following the announcement of the achievement of the primary endpoint and topline clinical study results from the NEPHRO CRRT clinical study to negotiate a definitive agreement to acquire Talphera. CorMedix also has the right to nominate a representative to the Talphera Board of Directors." The current cash should be at approximately 20mil+/-. [https://ir.talphera.com/news-releases/news-release-details/talphera-announces-private-placement-financing-29-million-priced](https://ir.talphera.com/news-releases/news-release-details/talphera-announces-private-placement-financing-29-million-priced)
Some of the short positions on decent stocks is amazing. UFPT has like 20% of the float short. CRMD too. Interesting theory I heard: long short funds have been increasingly long on NVDA requiring more and more shorts to counter that position. However, the flip side is that of NVDA sells off, those funds will be forced to close those shorts which could lead to a really violent rally in small caps. IWM and oil both have near record short positions and could see similar rallies. Interesting theory, we'll see what happens with it.
CRMD: we're raising our guidance! Market: sell!
CRMD update on guidance: Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million Revised Full Year Financial Guidance Pro forma 2025 Revenue: $325 million – $350 million Pro forma 2025 Synergized Adjusted EBITDA: $165 million – $185 million DefenCath® 2025 Revenue: $200 million – $215 million
CRMD They have a drug that reduces infection during dialysis. They also just made an acquisition that expanded their portfolio. Trading around 7x forward earnings, even if they don't land any other clients for dialysis....which they likely will.
Definitely. I tend to have a lot of low beta larger names as well. Also, a lot of thinly traded names that move some what independently of the market. That helps. I'm resigned to the fact that I might have some ugly days on the trail though. CRMD went from $16.5 down to $9 in the time I've owned it. Small caps are an adventure.
Solid trio for medical. I've been accumulating shares of CRMD. They have a drug that greatly reduces infections during dialysis. Even if they sign no new clients they're at like 9-10x forward earnings. However, there's a lot of potential new customers so that could even be low. Also adding to UFPT. They do packaging for medical devices, sort of a MEDP type play, bit for devices instead of drugs.
NBIS is a weird one....I bought it at $23, which was below the value of its assets. I figured it was a solid risk/reward at that point. It's definitely gotten expensive since then, which is why it's so big for me. My recent buys are ABL, CRMD, and NE, as well as OPRA. I'm not able to make the leap to Japanese names unfortunately. However, I'm still finding plenty of value out there.
Great acquistion and I think this is a very good purchase for $CRMD. Its certaily going to be a long term hold for me
I firmly believe that the "everything is expensive" crowd just doesn't look at enough names. OPRA: rule of 40 web browser trading at 16.5x earnings. Also pays a 5% dividend. NXT: utility solar isn't as rough as residential, and this gem is trading at 14.7x earnings. ODD: cosmetics name with 25%+ annual growth, trading at 22x EV/earnings. That's not even counting names with cheap forward earnings like CRMD (6x) or ABL (7x). Like Peter Lynch, turn over rocks.
I'm out of CRMD now. I may be wrong but hate acquisitions and think this was not a good use of capital. Such a shame, I hope they prove me wrong
CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN® and REZZAYO™.
Where should I go balls deep into: Recursion pharmaceuticals or Tempus AI? I'm mid shaft into CRMD.
For pharma I would bet so. 🥭 explicitly said he wants meds American and be made in America. My money is on CRMD as they are in both markets under different labels.
Stealth accumulation of CRMD over the past few weeks. Earnings coming in good. Steady profit margin of 40-70% with increased Healthcare provider network. Earnings in 2 weeks. Forward PE of 7. Short interest at 11-20% This seems too easy. Check their SEC filings for their numbers and FDA for their regulatory exclusivity. The volume on bullish patterns inconsistent with regular volume. I put 6 bands down at 11.40. Do your own research, but this is definitely investment advice. Invest.